LY3022855 + tremelimumab

LY3022855 + tremelimumab is an investigational combination of two monoclonal antibodies for cancer immunotherapy. **LY3022855** is a human recombinant immunoglobulin G1 monoclonal antibody targeting the **colony-stimulating factor-1 receptor (CSF-1R)**, which is involved in the regulation of tumor-associated macrophage activity. Tremelimumab is a fully human monoclonal antibody targeting **cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)**, functioning as an **immune checkpoint inhibitor**. The combination is designed to synergistically reduce immunosuppression in the tumor microenvironment by depleting or inhibiting macrophages (via CSF-1R) and enhancing T-cell activity (via CTLA-4 inhibition). This regimen has been tested in early-phase studies for advanced solid tumors including non-small cell lung cancer and ovarian cancer, showing limited clinical activity but acceptable tolerability profiles[1][3].